Filing Flows › Viatris (VTRS) › Q3 2026 › vs Q3 2025
Viatris (VTRS) Q3 2026 vs Q3 2025 (year over year)
Viatris's revenue fell $10.4M (-0.3%) from $3.8B in Q3 2025 to $3.7B in Q3 2026. The biggest changes: Lipitor +$55.8M (+14%); Influvac ® −$34.8M (-28%); Brands +$24.6M (+1%).
Viatris, Q3 2026: revenue $3.7B (-0.3% year over year), operating margin 7.0%, net loss $325M, operating cash flow $899M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 21.7% | 17.5% | +4.2 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Brands | $2.5B | $2.4B | $24.6M | +1% |
| Lipitor | $452M | $396M | $55.8M | +14% |
| EpiPen® Auto-Injectors | $156M | $157M | −$1.4M | -0.9% |
| Lyrica ® | $114M | $126M | −$12.3M | -10% |
| Creon ® | $98.1M | $93.1M | $5.0M | +5% |
| Viagra ® | $94.1M | $105M | −$11.1M | -11% |
| Influvac ® | $90.6M | $125M | −$34.8M | -28% |
| Zoloft ® | $78.8M | $66.8M | $12.0M | +18% |
| Yupelri ® | $71.5M | $71.4M | $100K | +0.1% |
| Celebrex ® | $70.2M | $73.3M | −$3.1M | -4% |
| Effexor ® | $63.9M | $67.2M | −$3.3M | -5% |
| Revenue | $3.7B | $3.8B | −$10.4M | -0.3% |
| Net loss | $325M | $128M | $197M | +154% |
| Costs & expenses | $4.1B | $3.9B | $187M | +5% |
| Operating costs | $3.5B | $3.6B | −$93.1M | -3% |
| Interest & other, net | $134M | $187M | −$53.1M | -28% |
| Income tax | $453M | $120M | $333M | +277% |
| Cost of revenue | $2.3B | $2.4B | −$76.9M | -3% |
| Operating expenses | $1.2B | $1.2B | −$16.2M | -1% |
| Operating cash sources | $1.2B | $873M | $352M | +40% |
| Depreciation & amortization | $697M | $688M | $8.7M | +1% |
| Share-based compensation | $39.6M | $36.0M | $3.6M | +10% |
| Working capital & other | $488M | $149M | $339M | +228% |
| Net loss absorbed | $325M | $128M | $197M | +154% |
| Operating cash flow | $899M | $745M | $154M | +21% |
| Free cash flow (OCF − capex) | $814M | $658M | $156M | +24% |
| Capital expenditures | $85.7M | $86.8M | −$1.1M | -1% |
Questions
How much did Viatris's revenue grow year over year in Q3 2026?
Viatris's revenue fell $10.4M (-0.3%) from $3.8B in Q3 2025 to $3.7B in Q3 2026.
What drove Viatris's revenue change in Q3 2026?
Lipitor +$55.8M (+14%); Influvac ® −$34.8M (-28%); Brands +$24.6M (+1%).